Fisher & Paykel Healthcare (ASX:FPH) GF Value Rank: 7 (As of Jul. 11, 2026) — 17% Above Median


ASX:FPH Fisher & Paykel Healthcare Corp Ltd ASX:FPH
90 GF Score
Price A$32.93
GF Value A$36.44
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Fisher & Paykel Healthcare GF Value Rank?

Fisher & Paykel Healthcare ASX:FPH -0.24% 90 GF Value Rank is 7 as of Jul. 11, 2026, which is 17% above its 10-year median of 6.00. GuruFocus rates ASX:FPH with a GF Score™ of 90/100 and a GF Value™ of A$36.44 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Fisher & Paykel Healthcare has the GF Value Rank of 7.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Fisher & Paykel Healthcare GF Value Rank Related Terms


ASX:FPH vs ISRG, BDX, MDLN: GF Value Rank Comparison

For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fisher & Paykel Healthcare GF Value Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Fisher & Paykel Healthcare's GF Value Rank falls into.


ASX:FPH
90GF Score
Fisher & Paykel Healthcare Corp Ltd ASX:FPH
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 7 mean?
Fisher & Paykel Healthcare (ASX:FPH) has a GF Value Rank of 7 as of Jul. 11, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Fisher & Paykel Healthcare and its competitors. This is 17% above median its historical median of 6.00. Over the past decade, Fisher & Paykel Healthcare's GF Value Rank has ranged from 1.00 to 10.00.
Is Fisher & Paykel Healthcare's GF Value Rank too high?
Fisher & Paykel Healthcare's current GF Value Rank of 7 is 17% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Fisher & Paykel Healthcare has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's GF Value Rank compare to ISRG and BDX?
Fisher & Paykel Healthcare's GF Value Rank of 7 can be compared against companies in the Medical Devices & Instruments industry. Historically, Fisher & Paykel Healthcare's own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Medical Devices & Instruments company?
A good GF Value Rank depends on the Medical Devices & Instruments industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Fisher & Paykel Healthcare and its competitors. Fisher & Paykel Healthcare's current GF Value Rank is 7, which is 17% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (ASX:FPH) is currently considered Modestly Undervalued. The stock's GF Value™ is A$36.44, compared to a current price of A$32.93 — trading 9.6% below its estimated fair value. The current GF Value Rank is 7, which is 17% above median its 10-year median of 6.00. Fisher & Paykel Healthcare's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Fisher & Paykel Healthcare (ASX:FPH), the current GF Value Rank is 7 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fisher & Paykel Healthcare (ASX:FPH) Overvalued in 2026?

Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued. The current stock price of A$32.93 is trading 9.6% below its estimated GF Value™ of A$36.44. GuruFocus considers Fisher & Paykel Healthcare to be Modestly Undervalued.

Key valuation signals for ASX:FPH:

  • GF Value Rank: 7 (17% above median its 10-year median of 6.00)
  • GF Value™: A$36.44 vs. price of A$32.93 (9.6% below fair value)
  • GF Score™: 90/100 with 2 warning signs

No single metric tells the full story. See the ASX:FPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fisher & Paykel Healthcare Business Description

Other Exchanges FSPKF:USAFPH:New Zealand
Address 15 Maurice Paykel Place, East Tamaki, Auckland, NTL, NZL, 2013
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
90GF Score

Get the complete analysis for ASX:FPH

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$32.93
Price
A$36.44
GF Value